AR043216A1 - Esteres activados de polietilenglicol - Google Patents

Esteres activados de polietilenglicol

Info

Publication number
AR043216A1
AR043216A1 ARP040100501A ARP040100501A AR043216A1 AR 043216 A1 AR043216 A1 AR 043216A1 AR P040100501 A ARP040100501 A AR P040100501A AR P040100501 A ARP040100501 A AR P040100501A AR 043216 A1 AR043216 A1 AR 043216A1
Authority
AR
Argentina
Prior art keywords
polyethylene glycol
oxalate
esters
active
peg
Prior art date
Application number
ARP040100501A
Other languages
English (en)
Spanish (es)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of AR043216A1 publication Critical patent/AR043216A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
ARP040100501A 2003-02-19 2004-02-18 Esteres activados de polietilenglicol AR043216A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44835403P 2003-02-19 2003-02-19

Publications (1)

Publication Number Publication Date
AR043216A1 true AR043216A1 (es) 2005-07-20

Family

ID=32908577

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100501A AR043216A1 (es) 2003-02-19 2004-02-18 Esteres activados de polietilenglicol

Country Status (9)

Country Link
US (1) US7094872B2 (https=)
EP (1) EP1597299A2 (https=)
JP (1) JP2006517995A (https=)
AR (1) AR043216A1 (https=)
BR (1) BRPI0407511A (https=)
CA (1) CA2515612A1 (https=)
MX (1) MXPA05008785A (https=)
TW (1) TW200426155A (https=)
WO (1) WO2004074345A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1259563T4 (en) 1999-12-22 2016-11-21 Nektar Therapeutics PROCEDURE FOR PREPARING 1-BENZOTRIAZOLYL CARBONATE ESTERS OF WATER SOLUBLE POLYMERS
ATE371680T1 (de) 2002-01-16 2007-09-15 Biocompatibles Uk Ltd Polymerkonjugate
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
ITPD20040159A1 (it) * 2004-06-21 2004-09-21 Univ Degli Studi Trieste Derivati bifunzionali del polietilenglicole loro preparazione e uso.
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
JP2007209543A (ja) * 2006-02-09 2007-08-23 Hidetoshi Tsuchida 表面修飾アルブミンからなる固相膜および酸素吸着膜
JP2009533347A (ja) 2006-04-07 2009-09-17 ネクター セラピューティックス エイエル,コーポレイション 抗TNFα抗体の複合体
EP4089133A1 (en) * 2021-05-14 2022-11-16 Johannes Gutenberg-Universität Mainz Poly(ethylene glycol) having c1 to c3-alkyloxymethyl side chains, bioconjugates thereof, process for its preparation and its use.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
JPH07500315A (ja) * 1991-05-10 1995-01-12 セルトリックス ファーマシューティカルズ,インコーポレイテッド 骨成長因子の標的送達
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
MXPA05008785A (es) 2005-10-18
US7094872B2 (en) 2006-08-22
TW200426155A (en) 2004-12-01
CA2515612A1 (en) 2004-09-02
WO2004074345A3 (en) 2005-01-20
JP2006517995A (ja) 2006-08-03
US20040162388A1 (en) 2004-08-19
EP1597299A2 (en) 2005-11-23
BRPI0407511A (pt) 2006-02-14
WO2004074345A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
DK0695759T3 (da) Peptapeptid-methylestere, der inhiberer human cancer
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
PE20020908A1 (es) Produccion recombinante de polimeros polianionicos y uso de de los mismos
WO2006081249A8 (en) Conjugates of biologically active proteins having a modified in vivo half-life
CY1114244T1 (el) Σκευασματα ανταγωνιστη vegf καταλληλα για ενδοϋαλωδη χορηγηση
ATE252601T1 (de) Lang wirkende insulinotrope peptide
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
EP2062976A3 (en) Site specific incorporation of keto amino acids into proteins
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
ES2051806T3 (es) Preparados de proteina humana estables.
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
WO2001041812A3 (en) Amphiphilic polymers and polypeptide conjugates comprising same
UA91575C2 (ru) Дендример-пег с четырьмя ветвями для коньюгирования с белками и пептидами
AR043216A1 (es) Esteres activados de polietilenglicol
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
NO20073914L (no) Biologisk aktive peptider
DE59906362D1 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
EP1080724A4 (en) COMPOSITIONS FOR REDUCING MTP ACTIVITY
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
ATE395101T1 (de) Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
RU2003125460A (ru) Биологически активный комплекс, содержащий фосфолипиды, для терапевтического использования
CO5300464A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту

Legal Events

Date Code Title Description
FB Suspension of granting procedure